Pacira BioSciences reported a second-quarter profit of $4.65 million, or $0.12 per share, swinging from a loss of $4.85 million, or $0.11 per share, a year earlier. Total revenue rose 6% to $192.40 million, driven by higher product sales and $1.91 million in royalty revenue. EXPAREL sales increased 3.4% to $147.82 million, while ZILRETTA sales edged up to $32.65 million. The company completed the divestiture of its Iovera business to Zimmer Biomet for $73.6 million in cash at closing, with potential milestone payments of up to $70 million. Following the divestiture, Pacira revised its full-year 2026 total revenue guidance to a range of $735 million to $760 million, down from the prior range of $745 million to $770 million, and projects EXPAREL net product sales of $600 million to $620 million.
Pacira BioSciences, Inc.Pacira swung to a profit and raised revenue guidance, though full-year guidance was revised down due to the Iovera divestiture.
Zimmer Biomet Holdings IncZimmer Biomet acquired Iovera for $73.6 million cash plus potential milestones, expanding its portfolio.
